Serum omentin, resistin and tumour necrosis factor-α levels in Behcet patients with and without ocular involvement

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 253, Issue 9, 2015, Pages 1565-1568

  Türkcü, Fatih Mehmet ^a   Şahin, Alparslan ^a   Cingü, Abdullah Kürşat ^a   Kaya, Savaş ^a   Yüksel, Hatice ^a   Cinar, Yasin ^a   Batmaz, İbrahim ^a  

^a DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Behcet disease; Omentin; Resistin; Tumour necrosis factor

Indexed keywords

ADIPOCYTOKINE; OMENTIN; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN; RETN PROTEIN, HUMAN;

ADULT; ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; EYE DISEASE; FEMALE; HUMAN; INFLAMMATION; IRIDOCYCLITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETINA VASCULITIS; UVEITIS; VITRITIS; BEHCET SYNDROME; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY;

ADULT; BEHCET SYNDROME; BIOMARKERS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GPI-LINKED PROTEINS; HUMANS; LECTINS; MALE; RESISTIN; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 84940440521     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-015-3016-0     Document Type: Article

References (26)

1. Geri G, Terrier B, Rosenzwajg M et al (2011) Critical role of IL-21 in modulating TH17 and regulatory T cells in Behcet disease. J Allergy Clin Immunol 128:655–664
2. Gürler A, Boyvat A, Türsen U (1997) Clinical manifestations of Behcet’s disease: an analysis of 2147 patients. Yonsei Med J 38:423–427
3. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M (2004) Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380
4. Sayinalp N, Oezcebe OI, Oezdemir O, Haznedaroglu CH, Dundar S, Kirazli S (1996) Cytokines in Behcet’s disease. J Rheumatol 23:321–322
5. Imamura Y, Kurokawa MS, Yoshikawa H et al (2005) Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet’s disease. Clin Exp Immunol 139:371–378
6. Direskeneli H, Fujita H, Akdis CA (2011) Regulation of TH17 and regulatory T cells in patients with Behcet disease. J Allergy Clin Immunol 128:665–666
7. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA (2004) An inflammatory cascade leading to Hyperresistinemia in humans. PLoS Med 1:e45
8. Pehlivan Y, Onat AM, Okumuş S et al (2012) The role of resistin in Behçet’s disease: a Turkish experiment. Mod Rheumatol 22:571–575
9. Yalçindag FN, Yalçindag A, Batioglu F, Caglayan O, Kisa U, Ozdemir O (2008) Evaluation of serum resistin levels in patients with ocular and non-ocular Behçet’s disease. Can J Ophthalmol 43:473–475
10. de Souza Batista CM, Yang RZ, Lee MJ et al (2007) Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56:1655–1661
11. Zhong X, Li X, Liu F, Tan H, Shang D (2012) Omentin inhibits TNF-a-induced expression of adhesion molecules in endothelial cells via ERK/NF-jB pathway. Biochem Biophys Res Commun 425:401–406
12. Teles FR, Teles RP, Martin L, Socransky SS, Haffajee AD (2012) Relationships among IL-6, TNF-α, Adipokines, vitamin D and chronic periodontitis. J Periodontol 83:1183–1191
13. International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080
14. Mege JL, Dilsen N, Sanguedolce V et al (1993) Overproduction of monocyte derived TNF, interleukin (IL) 6, IL 8 and increased neutrophil superoxide generation in Behçet’s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 20:1544–1549
15. Zhang M, Xu WD, Wen PF et al (2013) Polymorphisms in the tumor necrosis factor gene and susceptibility to Behcet’s disease: an updated meta-analysis. Mol Vis 19:1913–1924
16. Misumi M, Hagiwara E, Takeno M et al (2003) Cytokine production profile in patients with Behcet’s disease treated with infliximab. Cytokine 24:210–218
17. Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D (2012) New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev 11:687–698
18. Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA (2006) Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 12:100–105
19. Senolt L, Housa D, Vernerova Z et al (2007) Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 66:458–463
20. Kim SK, Choe JY, Park SH, Lee SW, Lee GH, Chung WT (2010) Increased insülin resistance and serum resistin in Korean patients with Behçet’s disease. Arch Med Res 41:269–274
21. Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y (2011) Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 408:339–343
22. Kazama K, Usui T, Okada M, Hara Y, Yamawaki H (2012) Omentin plays an antiinflammatory role through inhibition of TNF-α-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol 686:116–123
23. Lu Y, Zhou L, Liu L et al (2014) Serum Omentin-1 as a disease activity marker for Crohn’s disease. Dis Markers 2014:162517. doi:10.1155/2014/162517
24. Ismail SA, Mohamed SA (2012) Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity. Br J Dermatol 167:436–439
25. Senolt L, Polanská M, Filková M et al (2010) Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. Ann Rheum Dis 69:1410–1411
26. Yamawaki H (2011) Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull 34:307–310